
Rosuvastatin (10mg) + Aspirin (75mg) + Clopidogrel (75mg)
Active composition
+2 more active ingredients
Rosuvastatin inhibits HMG-CoA reductase, decreasing cholesterol synthesis in the liver and increasing LDL receptor expression.
Aspirin irreversibly inhibits COX-1 and COX-2 enzymes, leading to decreased production of thromboxane A2 and prostaglandins.
Clopidogrel irreversibly inhibits the P2Y12 component of ADP receptors on platelets, preventing platelet activation and aggregation.
Medical applications
Yogaros Gold 75mg/10mg/75mg Capsule is a combination pharmaceutical formulation containing Aspirin (75mg), Rosuvastatin (10mg), and Clopidogrel (75mg), indicated for the prevention and management of cardiovascular diseases. Aspirin, a well-known antiplatelet agent, inhibits cyclooxygenase enzymes, thereby reducing thromboxane A2 synthesis and preventing platelet aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels, contributing to the stabilization of atherosclerotic plaques and reduction of cardiovascular risk. Clopidogrel, another antiplatelet agent, selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, preventing platelet activation and aggregation. The synergistic action of these three active ingredients makes Yogaros Gold suitable for patients at high risk of thrombotic events, including those with a history of myocardial infarction, stroke, or peripheral arterial disease. This combination therapy aids in reducing the incidence of major adverse cardiovascular events by targeting multiple pathways involved in thrombosis and lipid metabolism. Yogaros Gold should be administered under medical supervision, with careful monitoring for potential adverse effects such as bleeding, myopathy, or hepatic dysfunction. It is contraindicated in patients with active bleeding, hypersensitivity to any component, or severe liver impairment.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Safety information not available for this product. Please consult your doctor or pharmacist.
0 reviews for Yogaros Gold 75mg/10mg/75mg Capsule

Aspirin (75mg) + Rosuvastatin (10mg) + Clopidogrel (75mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+2 more active ingredients
Rosuvastatin inhibits HMG-CoA reductase, decreasing cholesterol synthesis in the liver and increasing LDL receptor expression.
Aspirin irreversibly inhibits COX-1 and COX-2 enzymes, leading to decreased production of thromboxane A2 and prostaglandins.
Clopidogrel irreversibly inhibits the P2Y12 component of ADP receptors on platelets, preventing platelet activation and aggregation.
Medical applications
Yogaros Gold 75mg/10mg/75mg Capsule is a combination pharmaceutical formulation containing Aspirin (75mg), Rosuvastatin (10mg), and Clopidogrel (75mg), indicated for the prevention and management of cardiovascular diseases. Aspirin, a well-known antiplatelet agent, inhibits cyclooxygenase enzymes, thereby reducing thromboxane A2 synthesis and preventing platelet aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels, contributing to the stabilization of atherosclerotic plaques and reduction of cardiovascular risk. Clopidogrel, another antiplatelet agent, selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, preventing platelet activation and aggregation. The synergistic action of these three active ingredients makes Yogaros Gold suitable for patients at high risk of thrombotic events, including those with a history of myocardial infarction, stroke, or peripheral arterial disease. This combination therapy aids in reducing the incidence of major adverse cardiovascular events by targeting multiple pathways involved in thrombosis and lipid metabolism. Yogaros Gold should be administered under medical supervision, with careful monitoring for potential adverse effects such as bleeding, myopathy, or hepatic dysfunction. It is contraindicated in patients with active bleeding, hypersensitivity to any component, or severe liver impairment.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Safety information not available for this product. Please consult your doctor or pharmacist.
0 reviews for Yogaros Gold 75mg/10mg/75mg Capsule















